Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program
The Medicare GLP-1 Bridge program will provide access to Lilly's obesity treatments, Foundayo and Zepbound, for eligible Medicare Part D patients starting July 1.
Therapeutic Area
Therapeutic area intelligence for GLP-1 Agonists with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, indicating no clinical need for compounding these drugs.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.